Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project With Boston Scientific's Innova Drug Eluting Stent
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Arterial occlusive disorders; Vascular restenosis
- Focus Therapeutic Use
- Acronyms MAJESTIC
- Sponsors Boston Scientific Corporation
- 08 Mar 2017 Status changed to completed.
- 22 Feb 2016 According to Boston Scientific Corporation media release, based on data of this (MAJESTIC) trial, Eluvia Stent System received CE Mark approval.
- 28 Sep 2015 According to Boston Scientific Corporation media release, data from this trial will support global regulatory submission.